These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 36615199)

  • 21. Block-And-Lock: New Horizons for a Cure for HIV-1.
    Moranguinho I; Valente ST
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33334019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
    Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
    Kim Y; Anderson JL; Lewin SR
    Cell Host Microbe; 2018 Jan; 23(1):14-26. PubMed ID: 29324227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections.
    Yang H; Li X; Yang X; Lu P; Wang Y; Jiang Z; Pan H; Zhao L; Zhu Y; Khan IU; Shen Y; Lu H; Zhang T; Jiang G; Ma Z; Wu H; Zhu H
    Antiviral Res; 2019 Sep; 169():104555. PubMed ID: 31295520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
    Gupta V; Dixit NM
    PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV latency reversal agents: A potential path for functional cure?
    Lopes JR; Chiba DE; Dos Santos JL
    Eur J Med Chem; 2021 Mar; 213():113213. PubMed ID: 33540228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
    Shan L; Siliciano RF
    Bioessays; 2013 Jun; 35(6):544-52. PubMed ID: 23613347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.
    Painter MM; Zaikos TD; Collins KL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells.
    Piekna-Przybylska D; Bambara RA; Maggirwar SB; Dewhurst S
    Cell Cycle; 2020 Sep; 19(18):2298-2313. PubMed ID: 32807015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.
    Suryawanshi P; Bagul R; Shete A; Thakar M
    Front Immunol; 2021; 12():663919. PubMed ID: 33995393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CPI-637 as a Potential Bifunctional Latency-Reversing Agent That Targets Both the BRD4 and TIP60 Proteins.
    Zheng T; Chen P; Huang Y; Qiu J; Zhou C; Wu Z; Li L
    Front Cell Infect Microbiol; 2021; 11():686035. PubMed ID: 34350133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanoparticle-Based Immunoengineered Approaches for Combating HIV.
    Bowen A; Sweeney EE; Fernandes R
    Front Immunol; 2020; 11():789. PubMed ID: 32425949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diversity of small molecule HIV-1 latency reversing agents identified in low- and high-throughput small molecule screens.
    Hashemi P; Sadowski I
    Med Res Rev; 2020 May; 40(3):881-908. PubMed ID: 31608481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.
    López-Huertas MR; Gutiérrez C; Madrid-Elena N; Hernández-Novoa B; Olalla-Sierra J; Plana M; Delgado R; Rubio R; Muñoz-Fernández MÁ; Moreno S
    Sci Rep; 2020 Dec; 10(1):22286. PubMed ID: 33339855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Finding a cure for HIV: will it ever be achievable?
    Lewin SR; Evans VA; Elliott JH; Spire B; Chomont N
    J Int AIDS Soc; 2011 Jan; 14():4. PubMed ID: 21255462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
    Bullen CK; Laird GM; Durand CM; Siliciano JD; Siliciano RF
    Nat Med; 2014 Apr; 20(4):425-9. PubMed ID: 24658076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.